GlaxoSmithKline's Japan Survey Indicates 30% of Patients Taking Benzodiazepine Anxiolytic Suffer from Depression.Tokyo, Japan, Sept 21, 2005 - (JCNN JCNN Japan Corporate News Network ) - GlaxoSmithKline has announced the results of its recent Internet survey of 116,796 people in Japan on indefinite complaints. Of the respondents, 429 people answered that they have continuously taken benzodiazepine benzodiazepine (bĕn'zōdīăz`əpēn'), any of a class of drugs prescribed for their tranquilizing, antianxiety, sedative, and muscle-relaxing effects. Benzodiazepines are also prescribed for epilepsy and alcohol withdrawal. anxiolytic anxiolytic /anx·io·lyt·ic/ (ang?ze-o-lit´ik) 1. antianxiety. 2. an antianxiety agent. anx·i·o·lyt·ic n. A drug that relieves anxiety. for more than one month and are prescribed with it for symptoms except depression. Specifically, 24.1% of those who continuously take benzodiazepine anxiolytic said that they are diagnosed as autonomic nerve imbalance, followed by insomnia, panic disorder, anxiety neurosis and menopause. Subsequently, the company had the 429 respondents check themselves using the Mini-International Neuropsychiatric neu·ro·psy·chi·a·try n. The medical study of disorders with both neurological and psychiatric features. neu Interview (M.I.N.I), a short structured diagnostic interview developed in 1990. The interview results revealed that 8.8% of them suffer from major depression and 20.1% are in a state of depression. Based on the results, the company indicated that there is a danger to overlook the development of depression by treating patients who have indefinite complaints with symptomatic treatments such as dosing benzodiazepine anxiolytic. When asked why they began taking benzodiazepine, most of the respondents mentioned their physical symptoms such as sleeping difficulty, anxiety, palpitation palpitation (păl'pĭtā`shən), abnormal heartbeat that is often associated with a sensation of fluttering or thumping. The normal heartbeat is not noticeable to the individual. and dizziness rather than their psychiatric symptoms appeared. In addition, the respondents tend to take the anxiolytic for a long period of time. The average length of dosing is 4.2 years. In accordance with these findings, GlaxoSmithKline emphasizes that it is important for patients taking anxiolytics to consult a doctor with the premise that he or she may develop depression. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion